Nobasite, 250 mg 20 pcs.

Pharmacotherapeutic group: antiviral drug.

ATX code: J05AX

Pharmacological properties

Pharmacodynamics

Enisamy iodide is an antiviral agent derived from isonicotinic acid. It effectively suppresses action of influenza viruses and other pathogens of acute respiratory viral infections (ARI) due to the direct (inhibitory) influence on the process of virus penetration through the cell membrane.

It has interferonogenic properties and increases the concentration of endogenous interferon (interferon alpha and interferon gamma) in the blood plasma by 3-4 times.

Enhances resistance of the body to viral infections.

Limits acute clinical manifestations of viral intoxication, helps to reduce the duration of the disease.

Pharmacokinetics

After oral administration enisamide iodide quickly enters the blood, its maximum concentration in the blood is observed 2-2.5 hours after consumption. The elimination half-life is 13.5-14 hours, metabolized in the liver, but rapidly eliminated from the tissues (elimination half-life is 2-3 hours). It is excreted 90-95% in the urine as metabolites.

Indications

Active ingredient

Composition

1 tablet contains:

the core:

The active ingredient:

N-methyl-4-benzylcarbamidopyridinium iodide (enisamia iodide) (in terms of 100% anhydrous substance) – 125.0 mg/250.0 mg.

Auxiliary substances:

Lactose monohydrate – 33.4 mg/66.8 mg,

Microcrystalline cellulose 101 – 10.0 mg/20.0 mg,

sucrose (sugar) – 9.0 mg/18.0 mg,

povidone K-17 (Plasdon K-17) – 3.6 mg/7.2 mg,

copovidone (Plasdon S-630) – 1.4 mg/2.8 mg,

crospovidone (Polyplasdon XL-10) – 3.8 mg/ 7.6 mg,

talc – 1.9 mg/3.8 mg,

calcium stearate – 1.9 mg/3.8 mg.

film coating:

Aquarius Prime BAN314047 Yellow – 6 mg/12 mg (hypromellose – 3.96 mg/7.92 mg, titanium dioxide – 1.3437 mg/2.6874 mg, caprylic/caprylate (caprylic/caprine triglyceride) –
0.54 mg/1.08 mg, iron oxide yellow dye – 0.042 mg/0.084 mg, iron oxide red dye – 0.0003 mg/0.0006 mg, quinoline yellow dye – 0.114 mg/0.228 mg).

How to take, the dosage

Start treatment at the first signs of the disease. If after 3 days of treatment there is no improvement or the symptoms worsen, or new symptoms appear, you should consult a doctor. Use the drug only according to the indications, route of administration, and dosage listed in the instructions.

NOBASIT® is taken orally after a meal, without chewing.

The maximum single dose is 1000 mg, the daily dose is 2000 mg.

Adults: 500 mg 3 times a day. The recommended course of treatment is from 5 to 7 days.

Children from 12 years of age 250 mg 3 times a day for 7 days.

Interaction

The interaction with other drugs is not well studied.

The drug NOBASIT® enhances the effect of antibacterial and immunomodulatory agents. It is advisable to combine this drug with ascorbic acid and other vitamins. NOBASIT® can also be administered simultaneously with recombinant interferon.

If you are using the above or other medicines (including over-the-counter medications), talk to your doctor before taking NOBASIT® .

Special Instructions

Caution should be exercised when prescribing the drug in patients with thyroid disorders, especially in hyperthyroidism.

Influence on ability to drive vehicles, mechanisms

The administration of enisamide iodide does not affect the ability to drive vehicles, mechanisms.

Synopsis

Circular biconvex film-coated tablets, yellow in color, with a light yellow to yellow or yellow with a greenish tint on the cross section.

Contraindications

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Sugarase/isomaltase deficiency, fructose intolerance.

Children under 12 years of age, pregnancy, breastfeeding period.

The presence of allergic reactions regardless of the nature of the allergen in the history.

Severe organic liver and kidney disorders.

With caution

Patients with thyroid disease, especially hyperthyroidism.

Side effects

Allergic reactions: hypersensitivity reactions, including skin rashes, urticaria, angioedema, itching.

Gastrointestinal tract: dry and bitter taste in the mouth, swelling of the oral mucosa, hypersalivation, yellow coloring of the tongue, nausea, vomiting, heartburn, abdominal pain, heaviness in the right subcostal area, diarrhea, abdominal bloating.

Respiratory system: shortness of breath, throat irritation.

In the post-registration period, the following adverse reactions have been reported in single cases: headache, dizziness, weakness, blood pressure fluctuations.

If you experience or worsen the side effects listed in the instructions, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

In case of overdose of the drug, an increase in the side effects described in the appropriate section is possible. If they occur, gastric lavage and symptomatic treatment are carried out.

Pregnancy use